Effect of Renal Impairment on the Pharmacokinetics and Pharmacodynamics of Verinurad, a Selective Uric Acid Reabsorption Inhibitor

被引：0
|
作者：
William B. Smith
Jesse Hall
Jolene K. Berg
Michal Kazimir
Amy Yamamoto
Susan Walker
Caroline A. Lee
Zancong Shen
David M. Wilson
Dongmei Zhou
Michael Gillen
Thomas C. Marbury
机构：
[1] University of TN Medical Center,Volunteer Research Group
[2] Ardea Biosciences,undefined
[3] Inc,undefined
[4] DaVita Clinical Research,undefined
[5] DaVita Clinical Research,undefined
[6] AstraZeneca Pharmaceuticals LP,undefined
[7] Orlando Clinical Research Center,undefined
来源：
Clinical Drug Investigation | 2018年 / 38卷
关键词：
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
页码：703 / 713
页数：10
相关论文
共 50 条
  • [1] Effect of Renal Impairment on the Pharmacokinetics and Pharmacodynamics of Verinurad, a Selective Uric Acid Reabsorption Inhibitor
    Smith, William B.
    Hall, Jesse
    Berg, Jolene K.
    Kazimir, Michal
    Yamamoto, Amy
    Walker, Susan
    Lee, Caroline A.
    Shen, Zancong
    Wilson, David M.
    Zhou, Dongmei
    Gillen, Michael
    Marbury, Thomas C.
    CLINICAL DRUG INVESTIGATION, 2018, 38 (08) : 703 - 713
  • [2] Pharmacokinetics, pharmacodynamics, and tolerability of verinurad, a selective uric acid reabsorption inhibitor, in healthy adult male subjects
    Shen, Zancong
    Gillen, Michael
    Miner, Jeffrey N.
    Bucci, Gail
    Wilson, David M.
    Hall, Jesse W.
    DRUG DESIGN DEVELOPMENT AND THERAPY, 2017, 11 : 2077 - 2086
  • [3] Pharmacokinetics, Pharmacodynamics, and Tolerability of Verinurad, a Selective Uric Acid Reabsorption Inhibitor, in Healthy Japanese Male Subjects
    Gillen, Michael
    Miner, Jeffrey N.
    Valdez, Shakti
    ARTHRITIS & RHEUMATOLOGY, 2016, 68
  • [4] Pharmacokinetics, Pharmacodynamics, and Tolerability of Verinurad, a Selective Uric Acid Reabsorption Inhibitor, in Healthy Adult Male Subjects
    Gillen, Michael
    Shen, Zangong
    Miner, Jeffrey N.
    ARTHRITIS & RHEUMATOLOGY, 2016, 68
  • [5] PHARMACOKINETICS, PHARMACODYNAMICS, AND TOLERABILITY OF VERINURAD (RDEA3170), A SELECTIVE URIC ACID REABSORPTION INHIBITOR, IN HEALTHY JAPANESE MALE SUBJECTS
    Gillen, M.
    Miner, J. N.
    Valdez, S.
    ANNALS OF THE RHEUMATIC DISEASES, 2017, 76 : 1366 - 1366
  • [6] Pharmacokinetics, pharmacodynamics, and tolerability of verinurad, a selective uric acid reabsorption inhibitor, in healthy Japanese and non-Asian male subjects
    Hall, Jesse
    Gillen, Michael
    Liu, Sha
    Miner, Jeffrey N.
    Valdez, Shakti
    Shen, Zancong
    Lee, Caroline
    DRUG DESIGN DEVELOPMENT AND THERAPY, 2018, 12 : 1799 - 1807
  • [7] PHARMACOKINETICS, PHARMACODYNAMICS, AND TOLERABILITY OF VERINURAD (RDEA3170), A SELECTIVE URIC ACID REABSORPTION INHIBITOR, IN HEALTHY ADULT MALE SUBJECTS
    Gillen, M.
    Shen, Z.
    Miner, J. N.
    ANNALS OF THE RHEUMATIC DISEASES, 2017, 76 : 1366 - 1366
  • [8] Metabolism and Disposition of Verinurad, a Uric Acid Reabsorption Inhibitor, in Humans
    Lee, Caroline A.
    Yang, Chun
    Shah, Vishal
    Shen, Zancong
    Wilson, David M.
    Ostertag, Traci M.
    Girardet, Jean-Luc
    Hall, Jesse
    Gillen, Michael
    DRUG METABOLISM AND DISPOSITION, 2018, 46 (05) : 532 - 541
  • [9] Pharmacokinetics, pharmacodynamics, and safety of lesinurad, a selective uric acid reabsorption inhibitor, in healthy adult males
    Shen, Zancong
    Rowlings, Colin
    Kerr, Brad
    Hingorani, Vijay
    Manhard, Kimberly
    Quart, Barry
    Yeh, Li-Tain
    Storgard, Chris
    DRUG DESIGN DEVELOPMENT AND THERAPY, 2015, 9 : 3423 - 3434
  • [10] The effect for hyperuricemia inpatient of uric acid overproduction type or in combination with topiroxostat on the pharmacokinetics, pharmacodynamics and safety of dotinurad, a selective urate reabsorption inhibitor
    Okui, Daisuke
    Sasaki, Tomomitsu
    Fushimi, Masahiko
    Ohashi, Tetsuo
    CLINICAL AND EXPERIMENTAL NEPHROLOGY, 2020, 24 (SUPPL 1) : 92 - 102
12345